- Home
- HIVE vs NPCE Comparison
HIVE vs NPCE Comparison
Compare HIVE & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- NPCE
- Stock Information
- Founded
- HIVE 1987
- NPCE 1997
- Country
- HIVE United States
- NPCE United States
- Employees
- HIVE N/A
- NPCE N/A
- Industry
- HIVE
- NPCE Medical Specialities
- Sector
- HIVE
- NPCE Health Care
- Exchange
- HIVE Nasdaq
- NPCE Nasdaq
- Market Cap
- HIVE 360.2M
- NPCE 424.1M
- IPO Year
- HIVE N/A
- NPCE 2021
- Fundamental
- Price
- HIVE $2.30
- NPCE $9.94
- Analyst Decision
- HIVE Strong Buy
- NPCE Buy
- Analyst Count
- HIVE 7
- NPCE 7
- Target Price
- HIVE $6.57
- NPCE $15.14
- AVG Volume (30 Days)
- HIVE 24.0M
- NPCE 411.2K
- Earning Date
- HIVE 08-11-2025
- NPCE 08-12-2025
- Dividend Yield
- HIVE N/A
- NPCE N/A
- EPS Growth
- HIVE N/A
- NPCE N/A
- EPS
- HIVE N/A
- NPCE N/A
- Revenue
- HIVE $115,279,000.00
- NPCE $84,306,000.00
- Revenue This Year
- HIVE $167.38
- NPCE $21.04
- Revenue Next Year
- HIVE $68.08
- NPCE $10.73
- P/E Ratio
- HIVE N/A
- NPCE N/A
- Revenue Growth
- HIVE 0.71
- NPCE 22.05
- 52 Week Low
- HIVE $1.26
- NPCE $5.45
- 52 Week High
- HIVE $5.54
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- HIVE 66.14
- NPCE 36.29
- Support Level
- HIVE $2.09
- NPCE $9.91
- Resistance Level
- HIVE $2.44
- NPCE $10.58
- Average True Range (ATR)
- HIVE 0.18
- NPCE 0.63
- MACD
- HIVE 0.04
- NPCE 0.03
- Stochastic Oscillator
- HIVE 80.46
- NPCE 19.29
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.